FTC Approves Final Consent Order in Telomerase Activation Sciences Deceptive Advertising Case

Share This Page

For Your Information

Following a public comment period, the Federal Trade Commission has approved a final consent order settling deceptive advertising charges against Telomerase Activation Sciences, Inc. and Noel Patton (collectively, TA Sciences).

According to the FTC’s February 2018 complaint, TA Sciences lacked the scientific evidence to support claims that its capsules, powder, and cream could provide a broad range of anti-aging and other health benefits. The complaint specifically addressed allegedly deceptive advertising and endorsements regarding the efficacy and health benefits of two products, TA-65MD, which comes in capsule and powder forms, and TA-65 for Skin, a topical cream.

The final order settling the FTC’s charges prohibits TA Sciences from making any representation about the health benefits, performance, efficacy, safety, or side effects of any covered product, including TA-65MD and TA-65 Skin, unless it is not misleading and is supported by competent and reliable scientific evidence.

It also prohibits TA Sciences from misrepresenting that any paid commercial advertising is independent programing, as well as failing to disclose any material connection between a product endorser and the company. Finally, it bars TA Sciences from misrepresenting that any endorser is an independent user of a product.

The Commission vote approving the final consent order and letter to the member of the public who commented was 2-0. (The staff contact is Andrew Wone, Bureau of Consumer Protection, 202-326-2934)

The Federal Trade Commission works to promote competition, and protect and educate consumers. You can learn more about consumer topics and file a consumer complaint online or by calling 1-877-FTC-HELP (382-4357). Like the FTC on Facebook, follow us on Twitter, read our blogs and subscribe to press releases for the latest FTC news and resources.

Contact Information

CONTACT FOR CONSUMERS:
Consumer Response Center
877-382-4357

CONTACT FOR NEWS MEDIA:
Mitchell J. Katz
Office of Public Affairs
202-326-2161